Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: PMN
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 6, 2017

ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board

May 31, 2017

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

May 25, 2017

Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May 2017 Edinburgh

May 24, 2017

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease

  • arrow_back
  • 1…
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy